• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢清除剂在肝硬化肝性脑病防治中的应用

Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.

机构信息

Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS, B0C 1H0, Canada.

出版信息

Drugs R D. 2021 Jun;21(2):123-132. doi: 10.1007/s40268-021-00345-4. Epub 2021 Apr 22.

DOI:10.1007/s40268-021-00345-4
PMID:33890246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8206241/
Abstract

Effective lowering of circulating ammonia is the mainstay strategy in the prevention and treatment of hepatic encephalopathy in cirrhosis and there is increasing interest in agents with the metabolic potential for the active removal of ammonia by the liver and skeletal muscle by agents including L-ornithine L-aspartate, branched-chain amino acids, as well as the re-purposing of benzoate and phenylacetate currently employed for the control of hyperammonaemia in congenital urea-cycle enzymopathies. Based upon results of multiple systematic reviews with meta-analyses, L-ornithine L-aspartate demonstrably lowers circulating ammonia in patients with cirrhosis with concomitantly improved mental status. Distinct mechanisms responsible include optimisation of hepatic metabolic pathways for ammonia removal as well as direct hepatoprotective effects involving the release of glutathione and of nitric oxide with beneficial effects on hepatic microcirculation. L-ornithine L-aspartate also prevents cirrhosis-related sarcopenia, leading to increased capacity for ammonia removal by skeletal muscle. Branched-chain amino acids continue to be prescribed as nutritional supplements with the potential to result in improvements in liver function. Sodium benzoate, glycerol phenylbutyrate and an analogous compound L-ornithine phenylacetate were also evaluated. Glycerol phenylbutyrate was the only agent with a beneficial effect on both hyperammonaemia and hepatic encephalopathy. None were superior to lactulose for the lowering of blood ammonia.

摘要

有效降低循环氨是预防和治疗肝硬化肝性脑病的主要策略,人们对具有代谢潜力的药物越来越感兴趣,这些药物可以通过肝脏和骨骼肌主动清除氨,包括 L-鸟氨酸 L-天冬氨酸、支链氨基酸,以及目前用于控制先天性尿素循环酶病高氨血症的苯甲酸钠和苯乙酸的再利用。基于多项系统评价和荟萃分析的结果,L-鸟氨酸 L-天冬氨酸可明显降低肝硬化患者的循环氨,同时改善精神状态。其作用机制包括优化肝脏氨去除的代谢途径,以及直接的肝保护作用,涉及谷胱甘肽和一氧化氮的释放,对肝微循环有有益影响。L-鸟氨酸 L-天冬氨酸还可预防肝硬化相关的肌肉减少症,从而增加骨骼肌对氨的清除能力。支链氨基酸继续作为营养补充剂被开处方,有可能改善肝功能。苯甲酸钠、甘油苯丁酸和类似的化合物 L-苯丙氨酸 L-鸟氨酸也进行了评估。甘油苯丁酸是唯一对高氨血症和肝性脑病均有有益作用的药物。没有一种药物在降低血氨方面优于乳果糖。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ce/8206241/c438d2b045cd/40268_2021_345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ce/8206241/71d1081543b9/40268_2021_345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ce/8206241/903287819499/40268_2021_345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ce/8206241/c438d2b045cd/40268_2021_345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ce/8206241/71d1081543b9/40268_2021_345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ce/8206241/903287819499/40268_2021_345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ce/8206241/c438d2b045cd/40268_2021_345_Fig3_HTML.jpg

相似文献

1
Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.代谢清除剂在肝硬化肝性脑病防治中的应用
Drugs R D. 2021 Jun;21(2):123-132. doi: 10.1007/s40268-021-00345-4. Epub 2021 Apr 22.
2
[Prevention and treatment of hepatic encephalopathy].[肝性脑病的防治]
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10):144-147. doi: 10.17116/jnevro2017117101144-147.
3
Novel Ammonia-Lowering Agents for Hepatic Encephalopathy.用于肝性脑病的新型降氨药物。
Clin Liver Dis. 2015 Aug;19(3):539-49. doi: 10.1016/j.cld.2015.04.008. Epub 2015 May 30.
4
L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.L-鸟氨酸苯乙酸盐(OP):一种治疗高氨血症和肝性脑病的新疗法。
Med Hypotheses. 2007;69(5):1064-9. doi: 10.1016/j.mehy.2006.12.061. Epub 2007 Apr 27.
5
Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.采用恒氨输注法在人体中定量测定氨清除率和生成率 - 肝硬化和靶向氨治疗的影响。
J Hepatol. 2023 Aug;79(2):340-348. doi: 10.1016/j.jhep.2023.03.042. Epub 2023 Apr 13.
6
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.鸟氨酸天门冬氨酸(LOLA)在肝性脑病中的药代动力学和药效学特性。
Drugs. 2019 Feb;79(Suppl 1):23-29. doi: 10.1007/s40265-018-1023-2.
7
Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.口服 L-鸟氨酸 L-天冬氨酸治疗高氨血症性肝性脑病肝硬化患者的疗效。
Ann Hepatol. 2011 Jun;10 Suppl 2:S55-9.
8
L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.精氨酸天门冬氨酸治疗慢性肝病肌少症:终结恶性循环。
Can J Gastroenterol Hepatol. 2019 Apr 28;2019:8182195. doi: 10.1155/2019/8182195. eCollection 2019.
9
L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.L-鸟氨酸-L-天冬氨酸输注治疗肝性脑病的疗效
J Coll Physicians Surg Pak. 2008 Nov;18(11):684-7.
10
Recent advances in the treatment of hyperammonemia.高氨血症治疗的最新进展。
Adv Drug Deliv Rev. 2015 Aug 1;90:55-68. doi: 10.1016/j.addr.2015.04.009. Epub 2015 Apr 17.

引用本文的文献

1
Asparaginase-associated hyperammonemia.天冬酰胺酶相关性高氨血症
Haematologica. 2025 Aug 1;110(8):1702-1709. doi: 10.3324/haematol.2025.287301. Epub 2025 Apr 24.
2
Chinese Guidelines on the Management of Hepatic Encephalopathy in Cirrhosis (2024).《肝硬化肝性脑病诊疗指南(2024年版)》
J Clin Transl Hepatol. 2025 Mar 28;13(3):253-267. doi: 10.14218/JCTH.2024.00484. Epub 2025 Feb 17.
3
The Role of the Urea Cycle in the Alzheimer's Disease Brain.尿素循环在阿尔茨海默病大脑中的作用。

本文引用的文献

1
Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.治疗轻微型肝性脑病的各种方案的疗效比较:一项系统评价和网络荟萃分析。
Clin Gastroenterol Hepatol. 2020 Apr;18(4):800-812.e25. doi: 10.1016/j.cgh.2019.08.047. Epub 2019 Aug 30.
2
Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.L-鸟氨酸 L-天冬氨酸预防肝硬化患者显性肝性脑病的有益作用:系统评价与荟萃分析。
Metab Brain Dis. 2020 Jan;35(1):75-81. doi: 10.1007/s11011-019-00463-8. Epub 2019 Jul 23.
3
J Neurochem. 2025 Mar;169(3):e70033. doi: 10.1111/jnc.70033.
4
Biomarkers of Frailty in Patients with Advanced Chronic Liver Disease Undergoing a Multifactorial Intervention Consisting of Home Exercise, Branched-Chain Amino Acids, and Probiotics.慢性肝病晚期患者多因素干预(家庭运动、支链氨基酸和益生菌)的虚弱生物标志物。
Biomolecules. 2024 Nov 6;14(11):1410. doi: 10.3390/biom14111410.
5
Prophylaxis of hepatic encephalopathy: current and future drug targets.预防肝性脑病:当前和未来的药物靶点。
Hepatol Int. 2024 Aug;18(4):1096-1109. doi: 10.1007/s12072-024-10647-9. Epub 2024 Mar 16.
6
Aspartic Acid in Health and Disease.健康与疾病中的天冬氨酸
Nutrients. 2023 Sep 17;15(18):4023. doi: 10.3390/nu15184023.
7
Portosystemic shunt placement reveals blood signatures for the development of hepatic encephalopathy through mass spectrometry.通过质谱分析发现,门体分流术的放置揭示了肝性脑病发展的血液特征。
Nat Commun. 2023 Aug 31;14(1):5303. doi: 10.1038/s41467-023-40741-9.
8
Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed.肝性脑病的临床试验:旧的、新的和借来的。
Neurochem Res. 2023 Aug;48(8):2309-2319. doi: 10.1007/s11064-023-03916-w. Epub 2023 Mar 28.
9
Muscle Amino Acid and Adenine Nucleotide Metabolism during Exercise and in Liver Cirrhosis: Speculations on How to Reduce the Harmful Effects of Ammonia.运动及肝硬化过程中的肌肉氨基酸和腺嘌呤核苷酸代谢:关于如何降低氨的有害影响的思考
Metabolites. 2022 Oct 13;12(10):971. doi: 10.3390/metabo12100971.
10
Hepatic encephalopathy.肝性脑病。
Nat Rev Dis Primers. 2022 Jun 23;8(1):43. doi: 10.1038/s41572-022-00366-6.
L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
精氨酸鸟氨酸(LOLA)治疗肝硬化肝性脑病的随机对照试验和荟萃分析结果。
Drugs. 2019 Feb;79(Suppl 1):31-37. doi: 10.1007/s40265-018-1024-1.
4
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.鸟氨酸天门冬氨酸(LOLA)在肝性脑病中的药代动力学和药效学特性。
Drugs. 2019 Feb;79(Suppl 1):23-29. doi: 10.1007/s40265-018-1023-2.
5
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology.肝硬化性肝性脑病:病理学与病理生理学。
Drugs. 2019 Feb;79(Suppl 1):17-21. doi: 10.1007/s40265-018-1017-0.
6
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.L-鸟氨酸 L-天冬氨酸(LOLA)作为治疗非酒精性脂肪性肝病的新方法。
Drugs. 2019 Feb;79(Suppl 1):39-44. doi: 10.1007/s40265-018-1020-5.
7
Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles.肝性脑病:定义、临床分级和诊断原则。
Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z.
8
Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues.肝硬化肝性脑病对生活质量问题的影响。
Drugs. 2019 Feb;79(Suppl 1):11-16. doi: 10.1007/s40265-018-1019-y.
9
Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.L-鸟氨酸L-天冬氨酸治疗肝硬化肝性脑病和高氨血症的疗效:随机对照试验的系统评价和荟萃分析
J Clin Exp Hepatol. 2018 Sep;8(3):301-313. doi: 10.1016/j.jceh.2018.05.004. Epub 2018 May 22.
10
L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.L-鸟氨酸L-天冬氨酸用于预防和治疗肝硬化患者的肝性脑病。
Cochrane Database Syst Rev. 2018 May 15;5(5):CD012410. doi: 10.1002/14651858.CD012410.pub2.